Sanofi and Regeneron's Dupixent Achieves Primary Objective in Phase 3 Study for Allergic Fungal Rhinosinusitis
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 07 2025
0mins
Source: NASDAQ.COM
Study Results: Sanofi's Dupixent, co-developed with Regeneron, met its primary endpoint in the phase 3 LIBERTY-AFRS-AIMS study for treating allergic fungal rhinosinusitis (AFRS) in patients aged 6 and older.
Treatment Efficacy: The study demonstrated significant improvements in symptoms such as sinus opacification, nasal congestion, and nasal polyps compared to a placebo.
Regulatory Update: The FDA has accepted the supplemental biologics license application for Dupixent, granting it priority review status.
Action Timeline: The target action date for the FDA's decision on Dupixent is set for February 28, 2026.
Analyst Views on SNY
Wall Street analysts forecast SNY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SNY is 78.52 USD with a low forecast of 57.00 USD and a high forecast of 116.57 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
2 Buy
3 Hold
0 Sell
Moderate Buy
Current: 46.500
Low
57.00
Averages
78.52
High
116.57
Current: 46.500
Low
57.00
Averages
78.52
High
116.57
About SNY
Sanofi SA is a France-based healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
